From: Update on the development of a novel dry cow therapy using a bismuth-based intramammary teat seal in combination with the bacteriocin lacticin 3147
Treatment
Quarters(n)
Clinical infections
Strep. dysgalactiae Mrecovered from non-clinical quarters (day 8)
Total infections
Teat seal
33
14
(42.4%)
6
20
(60.6%)
Teat seal plus lacticin
35
2
(5.7%)
0